CPX-351: a nanoscale liposomal co-formulation of daunorubicin and cytarabine with unique biodistribution and tumor cell uptake properties

References

• Tamma PD, Cosgrove SE, Maragakis LL. Combination therapy for treatment of infections with gram-negative bacteria. Clin Microbiol Rev. 2012;25(3):450–470. doi:10.1128/CMR.05041-1122763634
   PubMed Web of Science ®Google Scholar
• Johnson LB, Saravolatz LD. The quad pill, a once-daily combination therapy for HIV infection. Clin Infect Dis. 2014;58(1):93–98. doi:10.1093/cid/cit63724065329
   PubMed Web of Science ®Google Scholar
• Mokhtari RB, Homayouni TS, Baluch N, et al. Combination therapy in combating cancer. Oncotarget. 2017;8(23):38022–38043. doi:10.18632/oncotarget.1672328410237
   PubMedGoogle Scholar
• Chou TC. Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol Rev. 2006;58(3):621–681. doi:10.1124/pr.58.3.1016968952
   PubMed Web of Science ®Google Scholar
• Tolcher AW, Mayer LD. Improving combination cancer therapy: the CombiPlex development platform. Future Oncol. 2018;14(13):1317–1332. doi:10.2217/fon-2017-060729363994
   PubMed Web of Science ®Google Scholar
• Ashley JD, Quinlan CJ, Schroeder VA, et al. Dual carfilzomib and doxorubicin-loaded liposomal nanoparticles for synergistic efficacy in multiple myeloma. Mol Cancer Ther. 2016;15(7):1452–1459. doi:10.1158/1535-7163.MCT-15-086727196779
   PubMed Web of Science ®Google Scholar
• Liu GX, Fang GQ, Xu W. Dual targeting biomimetic liposomes for paclitaxel/DNA combination cancer treatment. Int J Mol Sci. 2014;15(9):15287–15303. doi:10.3390/ijms15091528725177862
   PubMed Web of Science ®Google Scholar
• American Cancer Society. What are the key statistics about acute myeloid leukemia?; 2017 Available from: https://www.cancer.org/cancer/acute-myeloid-leukemia/about/key-statistics.html. Accessed 127, 2018.
   Google Scholar
• Nagel G, Weber D, Fromm E, et al. Epidemiological, genetic, and clinical characterization by age of newly diagnosed acute myeloid leukemia based on an academic population-based registry study (AMLSG BiO). Ann Hematol. 2017;96(12):1993–2003. doi:10.1007/s00277-017-3150-329090343
   PubMed Web of Science ®Google Scholar
• Pulte D, Jansen L, Castro FA, et al. Survival in patients with acute myeloblastic leukemia in Germany and the United States: major differences in survival in young adults. Int J Cancer. 2016;139(6):1289–1296. doi:10.1002/ijc.3018627176899
   PubMedGoogle Scholar
• Wheatley K, Brookes CL, Howman AJ, et al. Prognostic factor analysis of the survival of elderly patients with AML in the MRC AML11 and LRF AML14 trials. Br J Haematol. 2009;145(5):598–605. doi:10.1111/j.1365-2141.2009.07663.x19344426
   PubMed Web of Science ®Google Scholar
• Mohammadi M, Cao Y, Glimelius I, Bottai M, Eloranta S, Smedby KE. The impact of comorbid disease history on all-cause and cancer-specific mortality in myeloid leukemia and myeloma - a Swedish population-based study. BMC Cancer. 2015;15:850. doi:10.1186/s12885-015-1584-326537111
   PubMed Web of Science ®Google Scholar
• Granfeldt Østgård LS, Medeiros BC, Sengeløv H. Epidemiology and clinical significance of secondary and therapy-related acute myeloid leukemia: A national population-based cohort study. J Clin Oncol. 2015;33(31):3641–3649. doi:10.1200/JCO.2014.60.089026304885
   PubMedGoogle Scholar
• National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®). Acute Myeloid Leukemia. Version 3.2018. 2018; NCCN.org.
   Google Scholar
• Fey MF, Buske C,ESMO Guidelines Working Group. Acute myeloblastic leukaemias in adult patients: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013;24(Suppl 6):vi138–vi143. doi:10.1093/annonc/mdt32023970018
   PubMedGoogle Scholar
• Rai RK, Holland JF, Glidewell OJ, et al. Treatment of acute myelocytic leukemia: a study by cancer and leukemia group B. Blood. 1981;58(6):1203–1212.6946847
   PubMed Web of Science ®Google Scholar
• Dohner H, Weisdorf DJ, Bloomfield CD. Acute myeloid leukemia. N Engl J Med. 2015;373(12):1136–1152. doi:10.1056/NEJMra140618426376137
   PubMed Web of Science ®Google Scholar
• Yates JW, Wallace HJ Jr, Ellison RR, Holland JF. Cytosine arabinoside (NSC-63878) and daunorubicin (NSC-83142) therapy in acute nonlymphocytic leukemia. Cancer Chemother Rep. 1973;57(4):485–488.4586956
   PubMedGoogle Scholar
• Tardi P, Johnstone S, Harasym N, et al. In vivo maintenance of synergistic cytarabine: daunorubicin ratios greatly enhances therapeutic efficacy. Leuk Res. 2009;33(1):129–139. doi:10.1016/j.leukres.2008.06.02818676016
   PubMed Web of Science ®Google Scholar
• Vaughn JE, Othus M, Powell MA, et al. Comparative analysis of resource utilization and safety of outpatient management following intensive induction or salvage chemotherapy. JAMA Oncol. 2015;1(8):1120–1127. doi:10.1001/jamaoncol.2015.296926355382
   PubMed Web of Science ®Google Scholar
• Dicko A, Kwak S, Frazier AA, Mayer LD, Liboiron BD. Biophysical characterization of a liposomal formulation of cytarabine and daunorubicin. Int J Pharm. 2010;391(1–2):248–259. doi:10.1016/j.ijpharm.2010.02.01420156541
   PubMedGoogle Scholar
• Feldman EJ, Lancet JE, Kolitz JE, et al. First-in-man study of CPX-351: a liposomal carrier containing cytarabine and daunorubicin in a fixed 5:1 molar ratio for the treatment of relapsed and refractory acute myeloid leukemia. J Clin Oncol. 2011;29(8):979–985. doi:10.1200/JCO.2010.30.596121282541
   PubMed Web of Science ®Google Scholar
• Lancet JE, Uy GL, Cortes JE, et al. CPX-351 (Cytarabine: daunorubicin)liposome for injection versus conventional cytarabine plus daunorubicin in older patients with newly diagnosed secondary acute myeloid leukemia. J Clin Oncol. 2018;36(26):2684–2692. doi:10.1200/JCO.2017.77.611230024784
   PubMed Web of Science ®Google Scholar
• Cortes JE, Goldberg SL, Feldman EJ, et al. Phase II, multicenter, randomized trial of CPX-351 (cytarabine: daunorubicin) liposome injection versus intensive salvage therapy in adults with first relapse AML. Cancer. 2015;121(2):234–242. doi:10.1002/cncr.2897425223583
   PubMed Web of Science ®Google Scholar
• Breems DA, Van Putten WL, Huijgens PC, et al. Prognostic index for adult patients with acute myeloid leukemia in first relapse. J Clin Oncol. 2005;23(9):1969–1978. doi:10.1200/JCO.2005.06.02715632409
   PubMed Web of Science ®Google Scholar
• Lancet JE, Cortes JE, Hogge DE, et al. Phase 2 trial of CPX-351, a fixed 5:1 molar ratio of cytarabine/daunorubicin, vs cytarabine/daunorubicin in older adults with untreated AML. Blood. 2014;123(21):3239–3246. doi:10.1182/blood-2013-12-54097124687088
   PubMed Web of Science ®Google Scholar
• Kumar CC. Genetic abnormalities and challenges in the treatment of acute myeloid leukemia. Genes Cancer. 2011;2(2):95–107. doi:10.1177/194760191140807621779483
   PubMedGoogle Scholar
• Kolitz JE, Strickland SA, Cortes JE, et al. Efficacy by consolidation administration site: subgroup analysis of a phase 3 study of CPX-351 versus 7+3 in older adults with newly diagnosed, high-risk acute myeloid leukemia (AML). Presented at: Annual Meeting of the American Society of Clinical Oncology (ASCO); 61–5, 2017; Chicago, IL Abstract 7035.
   Google Scholar
• Mayer LD, Harasym TO, Tardi PG, et al. Ratiometric dosing of anticancer drug combinations: controlling drug ratios after systemic administration regulates therapeutic activity in tumor-bearing mice. Mol Cancer Ther. 2006;5(7):1854–1863. doi:10.1158/1535-7163.MCT-06-011816891472
   PubMed Web of Science ®Google Scholar
• Chou TC, Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul. 1984;22:27–55.6382953
   PubMedGoogle Scholar
• Mayer LD, Janoff AS. Optimizing combination chemotherapy by controlling drug ratios. Mol Interv. 2007;7(4):216–223. doi:10.1124/mi.7.4.817827442
   PubMedGoogle Scholar
• Harasym TO, Liboiron BD, Mayer LD. Drug ratio-dependent antagonism: a new category of multidrug resistance and strategies for its circumvention. Methods Mol Biol. 2010;596:291–323. doi:10.1007/978-1-60761-416-6_1319949929
   PubMedGoogle Scholar
• Koide H, Asai T, Hatanaka K, et al. T cell-independent B cell response is responsible for ABC phenomenon induced by repeated injection of PEGylated liposomes. Int J Pharm. 2010;392(1–2):218–223. doi:10.1016/j.ijpharm.2010.03.02220227473
   PubMedGoogle Scholar
• Feldman EJ, Kolitz JE, Trang JM, et al. Pharmacokinetics of CPX-351; a nano-scale liposomal fixed molar ratio formulation of cytarabine: daunorubicin, in patients with advanced leukemia. Leuk Res. 2012;36(10):1283–1289. doi:10.1016/j.leukres.2012.07.00622840315
   PubMed Web of Science ®Google Scholar
• Eloy JO, Claro de Souza M, Petrilli R, et al. Liposomes as carriers of hydrophilic small molecule drugs: strategies to enhance encapsulation and delivery. Colloids Surf B Biointerfaces. 2014;123:345–363. doi:10.1016/j.colsurfb.2014.09.02925280609
   PubMed Web of Science ®Google Scholar
• Tardi PG, Gallagher RC, Johnstone S, et al. Coencapsulation of irinotecan and floxuridine into low cholesterol-containing liposomes that coordinate drug release in vivo. Biochim Biophys Acta. 2007;1768(3):678–687. doi:10.1016/j.bbamem.2006.11.01417208196
   PubMedGoogle Scholar
• Agency for Toxic Substances and Disease Registry. Copper. 2017 Available from: https://www.atsdr.cdc.gov/substances/toxsubstance.asp?toxid=37. Accessed 1120, 2017.
   Google Scholar
• Lancet JE, Uy GL, Cortes JE, et al. Final results of a phase III randomized trial of CPX-351 versus 7+3 in older patients with newly diagnosed high risk (secondary) AML. J Clin Oncol. 2016;34(18 Suppl):7000. doi:10.1200/JCO.2016.34.15_suppl.7000
   Google Scholar
• Data on file. Jazz Pharmaceuticals, Inc., Palo Alto, CA.
   Google Scholar
• Lim WS, Tardi PG, Dos Santos N, et al. Leukemia-selective uptake and cytotoxicity of CPX-351, a synergistic fixed-ratio cytarabine: daunorubicin formulation, in bone marrow xenografts. Leuk Res. 2010;34(9):1214–1223. doi:10.1016/j.leukres.2010.01.01520138667
   PubMed Web of Science ®Google Scholar
• Medeiros BC, Hogge D, Newell LF, et al. Overall survival and transplantation in patients with FLT3 mutations: subgroup analysis of a Phase 3 study of CPX-351 versus 7+3 in older adults with newly diagnosed, high-risk acute myeloid leukemia. Presented at: 22nd Annual Congress of the European Hematology Association (EHA); 622–25, 2017; Madrid, Spain Abstract P210.
   Google Scholar
• Kim HP, Gerhard B, Harasym TO, Mayer LD, Hogge DE. Liposomal encapsulation of a synergistic molar ratio of cytarabine and daunorubicin enhances selective toxicity for acute myeloid leukemia progenitors as compared to analogous normal hematopoietic cells. Exp Hematol. 2011;39(7):741–750. doi:10.1016/j.exphem.2011.04.00121530609
   PubMed Web of Science ®Google Scholar
• Gordon MJ, Tardi P, Loriaux MM, et al. CPX-351 exhibits potent and direct ex vivo cytotoxicity against AML blasts with enhanced efficacy for cells harboring the FLT3-ITD mutation. Leuk Res. 2017;53:39–49. doi:10.1016/j.leukres.2016.12.00228013106
   PubMed Web of Science ®Google Scholar
• Lim WS, Tardi PG, Xie X, et al. Schedule- and dose-dependency of CPX-351, a synergistic fixed ratio cytarabine: daunorubicin formulation, in consolidation treatment against human leukemia xenografts. Leuk Lymphoma. 2010;51(8):1536–1542. doi:10.3109/10428194.2010.49031220528246
   PubMed Web of Science ®Google Scholar
• Marin JJ, Briz O, Rodriguez-Macias G, Diez-Martin JL, Macias RI. Role of drug transport and metabolism in the chemoresistance of acute myeloid leukemia. Blood Rev. 2016;30(1):55–64. doi:10.1016/j.blre.2015.08.00126321049
   PubMed Web of Science ®Google Scholar
• Chapuy B, Koch R, Radunski U, et al. Intracellular ABC transporter A3 confers multidrug resistance in leukemia cells by lysosomal drug sequestration. Leukemia. 2008;22(8):1576–1586. doi:10.1038/leu.2008.10318463677
   PubMed Web of Science ®Google Scholar
• Guo Y, Kock K, Ritter CA, et al. Expression of ABCC-type nucleotide exporters in blasts of adult acute myeloid leukemia: relation to long-term survival. Clin Cancer Res. 2009;15(5):1762–1769. doi:10.1158/1078-0432.CCR-08-044219240178
   PubMedGoogle Scholar
• van Den Heuvel-Eibrink MM, van der Holt B, Burnett AK, et al. CD34-related coexpression of MDR1 and BCRP indicates a clinically resistant phenotype in patients with acute myeloid leukemia (AML) of older age. Ann Hematol. 2007;86(5):329–337. doi:10.1007/s00277-007-0269-717340137
   PubMed Web of Science ®Google Scholar
• Chauhan PS, Bhushan B, Singh LC, et al. Expression of genes related to multiple drug resistance and apoptosis in acute leukemia: response to induction chemotherapy. Exp Mol Pathol. 2012;92(1):44–49. doi:10.1016/j.yexmp.2011.09.00422037714
   PubMedGoogle Scholar
• Jin G, Matsushita H, Asai S, et al. FLT3-ITD induces ara-C resistance in myeloid leukemic cells through the repression of the ENT1 expression. Biochem Biophys Res Commun. 2009;390(3):1001–1006. doi:10.1016/j.bbrc.2009.10.09419853583
   PubMed Web of Science ®Google Scholar
• Lin TL, Newell LF, Stuart RK, et al. CPX-351 (cytarabine: daunorubicin) liposome injection, (Vyxeos) does not prolong QTcF intervals, requires no dose adjustment for impaired renal function and induces high rates of complete remission in acute myeloid leukemia. Presented at: 57th Annual Meeting and Exposition of the American Society of Hematology (ASH); 125–8, 2015; Orlando, FL Abstract 2510.
   Google Scholar
• Liboiron BD, Louie AC, Mayer LD. Nanoscale complexes. A novel nanotechnology-based platform to optimize combination cancer therapies: rational development & improved delivery using CombiPlex®. Drug Dev Delivery. 2016;16(1):34–39.
   Google Scholar